INTRODUCTION
============

Paraneoplastic syndromes are associated with a wide range of diseases and/or symptoms that are not caused directly by the tumour or its metastases. They can result from the action of hormones, cytokines, and other substances produced by neoplastic cells, or are the consequence of the host's mechanisms directed against these cells. These manifestations tend to occur at sites that are distant from the tumour^\[[@b1-374-1-2612-1-10-20160223]\]^. Some may consist of a variety of musculoskeletal pathologies, and are, therefore, defined as paraneoplastic rheumatologic syndromes.

Polymyalgia rheumatica (PMR), a relatively common disease in the elderly, is characterized by stiffness and pain in the shoulders, neck, and hips.

The association between PMR and cancer is controversial, and it is based on temporal concurrence and corresponding clinical course between the two pathologies. Associations between PMR and haematological and solid malignant tumours have been described^\[[@b2-374-1-2612-1-10-20160223]\]^.

Paraneoplastic syndromes are important as they can represent the first presentation of an associated, and often occult, neoplasm^\[[@b3-374-1-2612-1-10-20160223]\]^.

CASE REPORT
===========

A 82-year-old man was admitted to the Emergency Department with a one-month history of pain, stiffness, and decreased range of motion affecting both shoulders and hips, which greatly limited daily activities. The patient had a past medical history of type 2 diabetes mellitus and essential hypertension, and was under medication with metformin 1000 mg twice daily, gliclazide 60mg/day, and lisinopril 20 mg/day.

Physical examination was remarkable for pain with movement and a markedly decreased active range of motion of the shoulder griddle.

Laboratory tests ([Table 1](#t1-374-1-2612-1-10-20160223){ref-type="table"}) revealed a normochromic, normocytic anaemia, an erythrocyte sedimentation rate (ESR) of 76 mm/h, and a C-reactive protein (CRP) 17.9× the upper limit of normal (ULN). The remaining laboratory tests, including serum protein electrophoresis, antinuclear antibodies, c and p-ANCAs, complement fractions, rheumatoid factor, and anti-CCP antibody, were unremarkable. Diagnosis of PMR was considered and deflazacort 12 mg/day was started.

Treatment improved some of the patients' complaints but failed to achieve complete symptom relief. Laboratory test results showed a mild decrease on ESR, with values between 53--59mm/h, while CRP values remained unchanged ([Table 1](#t1-374-1-2612-1-10-20160223){ref-type="table"}). Deflazacort was then increased to 18mg/day (with a "tighter" surveillance of glycaemic control) without further improvement.

Prompt investigation was carried out for an alternative diagnosis, and included Prostatic Specific Antigen (PSA), gastrointestinal endoscopy, chest x-ray, and abdominal ultrasound, all of which were unremarkable.

Five months later, the patient sought medical care for an acute episode of macroscopic haematuria. Further study with abdominal ultrasound *(*[Fig. 1](#f1-374-1-2612-1-10-20160223){ref-type="fig"}) showed a bladder mass (previously absent) that was confirmed by computed tomography scan to be suggestive of a bladder carcinoma extending to the surrounding fatty tissue layer ([Fig. 2](#f2-374-1-2612-1-10-20160223){ref-type="fig"}).

Radical cystectomy and prostatectomy were carried out and histology confirmed an infiltrative bladder carcinoma -- T3bN1M0 -- and a previously unknown prostate adenocarcinoma -- pT2aN0M0, Gleason 6.

A few weeks after surgery, deflazacort was suspended, and one month after discharge, the patient was asymptomatic and his inflammatory markers had improved: ESR of 38mm/h and CRP were negative.

DISCUSSION
==========

Paraneoplastic syndromes affect up to 8% of patients with an active cancer, most of the times preceding its diagnosis^\[[@b1-374-1-2612-1-10-20160223],[@b2-374-1-2612-1-10-20160223]\]^.

Its pathophysiology is not fully understood, but in the last decades, some mechanisms linking cancer to these syndromes have become clearer. It is accepted that soluble factors produced by the tumour and/or an immune/host reaction against tumour cells are involved^\[[@b1-374-1-2612-1-10-20160223],[@b4-374-1-2612-1-10-20160223]\]^.

These soluble factors can be peptides or hormones, the latter being the most important mechanism in endocrine paraneoplastic syndromes, such as Cushing syndrome. Immune-mediated paraneoplastic syndromes (e.g. rheumatologic paraneoplastic syndromes) are believed to be the result of a host's immunologic response against an underlying neoplasia. It has become clearer that tumour cells can adapt themselves in order to evade immunologic-driven destruction, in a process that was named "immunoediting" by *Dunn* and colleagues^\[[@b5-374-1-2612-1-10-20160223]\]^. This process has three stages: elimination, equilibrium, and escape. In the first stage, the immune response succeeds in eliminating the neoplasm; in the second stage, equilibrium between immune destruction and tumour growth is reached, preventing tumour development without eliminating it; and in the last stage, tumour cells manage to evade the immune system control and the tumour grows unrestrained. In the first two stages, the likely scenario is of an occult neoplasia and, therefore, patients are often diagnosed with clinical syndromes resulting from the distal manifestations of the underlying tumour, such as the case of paraneoplastic PMR.

Diagnosis of paraneoplastic rheumatic syndromes is therefore challenging, and is based on a time-relation scenario and some unusual manifestations of the presenting inflammatory musculoskeletal disease, such as rapid/agressive-onset of symptoms, atypical age group, poor response to corticosteroids or immunosuppressive therapy, atypical distribution of involved joints, and abnormal laboratory tests. Commonly associated neoplasms are haematolymphatic malignancies (1/3 of patients), followed by adenocarcinoma of the lung and breast (among others)^\[[@b1-374-1-2612-1-10-20160223],[@b3-374-1-2612-1-10-20160223]\]^. A group of reported cases in the literature linking PMR to malignant neoplasms is summarized in [Table 2](#t2-374-1-2612-1-10-20160223){ref-type="table"} - [Appendix](#app1-374-1-2612-1-10-20160223){ref-type="app"}.

In the present case, the lack of response to treatment and the improvement/resolution of the patient's complaints after surgery established the relationship between PMR and the underlying urothelial cancer/prostate adenocarcinoma, thus leading to the diagnosis of a paraneoplastic polymyalgia rheumatica.

Atypical PMR and, especially the lack of a dramatic treatment response, should prompt additional investigation for alternative diagnosis. Recognition of paraneoplastic rheumatic diseases may permit early diagnosis and treatment of the underlying cancer, as these syndromes, although rare, can be the first sign of an occult malignancy or its recurrence^\[[@b3-374-1-2612-1-10-20160223]\]^.
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###### 

Reports linking PMR and neoplasm

  Age    Sex      Atypical presenting features                              Cancer type                         Reference^\*^
  ------ -------- --------------------------------------------------------- ----------------------------------- ---------------------------------
  *72*   Male     Partial treatment response                                Epidermoid Carcinoma of the lung    [@b6-374-1-2612-1-10-20160223]
  *50*   Male     Absence of morning stiffness                              Multiple Myeloma                    [@b7-374-1-2612-1-10-20160223]
  *75*   Male     Peripheral joint synovitis + Lack of treatment response   Gastric Adenocarcinoma              [@b8-374-1-2612-1-10-20160223]
  *75*   Female   Corticosteroid dependence                                 Adenocarcioma of the colon          [@b9-374-1-2612-1-10-20160223]
  *48*   Female   Partial analytical response to treatment                  Renal adenocarcinoma                [@b10-374-1-2612-1-10-20160223]
  *74*   Female   Bicytopenia                                               Acute myeloid leukaemia             [@b11-374-1-2612-1-10-20160223]
  *59*   Female   Bicytopenia                                               Myelodysplastic syndrome            [@b12-374-1-2612-1-10-20160223]
  *54*   Female   Recurring symptoms on therapy                             Malignant adrenal cortical tumour   [@b13-374-1-2612-1-10-20160223]
                  High ALP levels                                                                               
  *63*   Female   Paraesthesia and palmar erythema of the left hand         Bronchi adenocarcinoma              [@b14-374-1-2612-1-10-20160223]
  *57*   Male     Peripheral joint synovitis                                Bronchi adenocarcinoma              
  *83*   Female   Lack of treatment response                                Pulmonary adenocarcinoma            [@b15-374-1-2612-1-10-20160223]
  *69*   Male     N/A                                                       Prostatic adenocarcinoma            [@b16-374-1-2612-1-10-20160223]

ALP = Alkaline phosphatase

![Bladder ultrasound revealing an urothelial carcinoma (white arrow).](374_Fig1){#f1-374-1-2612-1-10-20160223}

![Abdominal computed tomography-scan showing an invasive urothelial carcinoma of the bladder (white arrows).](374_Fig2){#f2-374-1-2612-1-10-20160223}

###### 

Laboratory test results. Deflazacorte dosage is underlined.

  ------------------------------- --------------------------- ---------- --------------------------- ---------- --------------------------------------------------------- ----------
  **Full blood count**            Haemoglobin (13--17 g/dl)   **11.3**   **Deflazacort 12--18 mg**   **12.6**   **Radical Cystoprostatectomy + Deflazacort suspension**   **12.8**
  MCV (83--101 fL)                94.9                        92.6       95.3                                                                                             
  Leukocytes (4--10×10\^9/L)      9.9                         **10.5**   7.5                                                                                              
                                                                                                                                                                          
  ESR (1--20 mm/h)                **76**                      **53**     **38**                                                                                           
                                                                                                                                                                          
  **Biochemistry**                CRP (0--0.5 mg/dl)          **8.95**   **8.93**                    **0.28**                                                             
  LDH (125--220 U/L)              158                         171        158                                                                                              
  CPK (\<171 U/L)                 38                          66         69                                                                                               
  ALP (40--150 U/L)               106                         84         112                                                                                              
  Creatinine (0.72--1.18 mg/dl)   0.84                        1.11       1.01                                                                                             
  Ferritin (20--250 ng/ml)        **255**                     **-**      **50**                                                                                           
                                                                                                                                                                          
  HbA1c (%)                       **7.7**                                **8.0**                                **7.8**                                                   
  PSA (\<4 ng/ml)                 **1**                       **1.1**    **\<0.1**                                                                                        
  ------------------------------- --------------------------- ---------- --------------------------- ---------- --------------------------------------------------------- ----------
